论文部分内容阅读
我们前瞻性观察β２－微球蛋白（β２－ＭＧ）在大剂量氨甲喋呤（ＨＤＭＴＸ）化疗时变化和血、尿β２－ＭＧ的相互关系，现将结果报告如下。１ 临床资料１．１ 对象 １９９７年１０月—１９９８年１１月，急性淋巴细胞性白血病２例，非霍奇金淋巴瘤１例。男１例，女２例。
We prospectively observed the relationship between β2-microglobulin (β2-MG) changes in high-dose methotrexate (HDMTX) chemotherapy and blood and urine β2-MG. The results are reported below. 1 Clinical data 1.1 Subjects From October 1997 to November 1998, there were 2 cases of acute lymphoblastic leukemia and 1 case of non-Hodgkin’s lymphoma. There were 1 male and 2 female.